Literature DB >> 1269194

Pharmacokinetics of methotrimeprazine after single and multiple doses.

S G Dahl.   

Abstract

Concentrations of methotrimeprazine and a metabolite, methotrimeprazine sulfoxide, were measured in plasma after a single intramuscular dose and after single and multiple oral doses of methotrimeprazine. The highest plasma concentrations of methotrimeprazine were found 30 to 90 min after intramuscular injection, and 1 to 3 hr after oral administration. On average 50% of orally administered drug reached the general circulation as unchanged methotrimeprazine. The apparent volume of distribution (Vbeta) was 23 to 42 L/kg body weight, and the biologic half-life, 15 to 30 hr. The sulfoxide could not be traced in plasma after a 25-mg intramuscular dose, but was found in higher plasma concentrations than the unmetabolized drug after single and multiple oral doses. This could be due to oxidation of the drug either in the gastrointestinal lumen or in the intestinal wall, or during its first passage through the liver. The apparent half-life of the sulfoxide was on average 30% shorter than the half-life of methotrimeprazine.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1269194     DOI: 10.1002/cpt1976194435

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup.

Authors:  S G Dahl; R E Strandjord; S Sigfusson
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

2.  Region specific distribution of levomepromazine in the human brain.

Authors:  J Kornhuber; H Weigmann; J Röhrich; J Wiltfang; S Bleich; I Meineke; R Zöchling; S Härtter; P Riederer; C Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

3.  The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.

Authors:  K K Midha; J W Hubbard; S R Marder; E M Hawes; T Van Putten; G McKay; P R May
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Drug metabolite concentration-time profiles: influence of route of drug administration.

Authors:  J B Houston; G Taylor
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

5.  Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution.

Authors:  Johannes Kornhuber; Jens Wiltfang; Peter Riederer; Stefan Bleich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

Review 6.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

7.  Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat.

Authors:  S G Dahl; H Hall
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 8.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

10.  Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man.

Authors:  G Taylor; J B Houston; J Shaffer; G Mawer
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.